During the stress response and metabolic fasting, glucocorticoids acting via the glucocorticoid receptor (GR) stimulate hepatic glucose production by activating specific gluconeogenic enzyme target genes. To characterize novel direct GR-regulated hepatic target genes under glucocorticoid control, we performed a whole genome gene expression microarray using dexamethasone-treated GR-null mice. Strongly induced previously characterized genes included phosphoenolpyruvate carboxykinase, serine dehydratase, tyrosine oxygenase, lipin 1, metallothionine, and cdkn1A. Novel induced genes included Ddit4, Fkbp5, Megf9, Sult1e1, and Sult1d1, and all were verified by real-time PCR. Sult1d1, a sulfotransferase, is a member of a large superfamily of detoxification enzymes and has an important role in the inactivation of endogenous dopamine-derived compounds, including the catecholamines. Treatment of primary mouse hepatocytes with dexamethasone for 6 h dramatically increased Sult1d1 mRNA levels, whereas cotreatment with RU-486, a GR antagonist, blocked induction by dexamethasone. Sult1d1 mRNA levels were also increased by dexamethasone in the kidney, a major site of Sult1d1 synthesis. Sult1d1 mRNA was localized by in situ hybridization to renal collecting ducts and was rapidly induced by glucocorticoids in renal inner medullary collecting duct (IMCD3) cells. Hepatic and renal Sult1d1 enzymatic activity was significantly induced in vivo in wild-type mice 6 h after dexamethasone treatment. Chromatin immunoprecipitation assay analysis upstream of the Sult1d1 gene promoter identified a glucocorticoid response element close to the neighboring glucocorticoid-responsive estrogen sulfotransferase Sult1e1 gene, indicating that both genes potentially share a common glucocorticoid response element. These results suggest that Sult1d1 in mice is directly induced by glucocorticoids and may attenuate elevated catecholamine activity during the stress response. (Endocrinology 151:  185-194, 2010) G lucocorticoids are critical for maintaining metabolic homeostasis and responding to stress and function via corticosteroid receptors by activating a large number of specific response genes within target cells. In conjunction with other hormones such as epinephrine, insulin, and glucagon, glucocorticoids regulate the levels of blood glucose in the body during fasting (1, 2) and play a key role in returning the body to homeostasis after acute stress. Neuroendocrine components of the response to stress increase the secretion of the catecholamines epinephrine and norepinephrine from the adrenal medulla and the sympathetic nervous system (3, 4). Release of catecholamines and glucocorticoids has been recognized to increase heart rate and blood pressure and increase the rate of gluconeogenesis in the liver, respectively. Glucocorticoids increase the specific activity of several key enzymes in the gluconeogenic pathway as well as enzymes involved in amino acid metabolism and the urea cycle that facilitate the delivery of substrates for hepatic glucose production (5).
G
lucocorticoids are critical for maintaining metabolic homeostasis and responding to stress and function via corticosteroid receptors by activating a large number of specific response genes within target cells. In conjunction with other hormones such as epinephrine, insulin, and glucagon, glucocorticoids regulate the levels of blood glucose in the body during fasting (1, 2) and play a key role in returning the body to homeostasis after acute stress. Neuroendocrine components of the response to stress increase the secretion of the catecholamines epinephrine and norepinephrine from the adrenal medulla and the sympathetic nervous system (3, 4) . Release of catecholamines and glucocorticoids has been recognized to increase heart rate and blood pressure and increase the rate of gluconeogenesis in the liver, respectively. Glucocorticoids increase the specific activity of several key enzymes in the gluconeogenic pathway as well as enzymes involved in amino acid metabolism and the urea cycle that facilitate the delivery of substrates for hepatic glucose production (5) .
Glucocorticoids act in target cells by binding to intracellular nuclear receptors termed glucocorticoid receptors (GRs), which function as ligand-activated nuclear transcription factors (6, 7) . A number of glucocorticoid-regulated hepatic gluconeogenic genes have been characterized that include tyrosine aminotransferase (TAT), phosphoenolpyruvate carboxykinase (PEPCK), serine dehydrogenase (SDH), G6Pase, and tryptophan oxygenase (TO; 8 -10) . In addition to these gluconeogenic enzyme genes, other identified hepatic glucocorticoid-regulated target genes include detoxification genes such as the metallothionein gene family, MT1 and MT2, which protect against metal toxicity, and Cyp3A (11) . More recently, a phase II estrogen-metabolizing enzyme called Sult1e1 has been described as a glucocorticoid-induced target in the liver (12) . Sult1e1 belongs to a class of enzymes called the sulfotransferases, which transfer a sulfate group from the coenzyme 3Ј-phosphoadenosine-5Ј-phosphosulfate (PAPS) to specific substrates such as endogenous proteins, lipids, or xenobiotic compounds (13) .
Although a number of glucocorticoid-responsive genes have been characterized, the complete sets of glucocorticoid-regulated genes in specific cells or tissues are unknown, particularly during the response to stress (14) . Identification of glucocorticoid-regulated genes in the liver is an essential step toward understanding the molecular mechanisms of glucocorticoid action during metabolism and after the response to acute stress.
To characterize novel glucocorticoid-regulated genes involved in the hepatic response to stress, we have used GR-null mice, which have previously been reported to have marked defects in the activation of hepatic gluconeogenic genes (15) . Although a majority of mice die at birth due to lung atelectasis, a small proportion of GR-null mice on a nonisogenic (129sv/C57Bl6) genetic background survive to adulthood. Using whole-genome gene expression microarray analysis with liver RNA from adult GR-null mice compared with wild-type mice 3 h after dexamethasone treatment, we have isolated novel hepatic GR-mediated gene targets. One such identified gene target was another member of the sulfotransferase gene family Sult1d1 whose levels were significantly induced after glucocorticoid treatment. This study has further characterized the glucocorticoid regulation of Sult1d1 in the liver and kidney, where it plays a role in the inactivation of endogenous dopamine compounds such as the catecholamines through sulfate conjugation. Investigation of the upstream promoter region of the Sult1d1 gene identified a glucocorticoid response element (GRE) potentially shared with the adjacent Sult1e1 gene, suggesting possible dual regulation of both genes via glucocorticoids in mouse liver. These findings have uncovered a unique GR-induced pathway regulating the sulfation and inactivation of catecholamines that may represent important endocrine cross talk during the systemic response to stress.
Materials and Methods

Mice
GR-null mice were generated by gene targeting (15) . On a complete 129sv genetic background, all GR-null mice die at birth due to respiratory dysfunction. The majority of mice on a nonisogenic 129sv-C57BL-6 background experienced the same lethality, but a small percentage (ϳ10%) survive birth and develop normally into adulthood. These mice were used for subsequent gene array studies (n ϭ 3 mice per group). Mice were injected ip with a single 100-l dose of 4 g/l dexamethasone over 0 h, 3 h, 6 h, and 24 h (n ϭ 3 mice per time point). In a separate series, C57Bl6 mice (n ϭ 4) were either treated with a 100-l dose of 4 g/l of dexamethasone or 0.1% PBS. Animal experimentation was approved by the institutional Animal Ethics Committee (project no. BAM/B/2007/48) at Monash University. Tail snips were genotyped at the GR locus by PCR (16) .
Isolation of mouse hepatocytes and culture in vitro
Hepatocytes were isolated from the liver of Balb/c mice using a modification of the collagenase perfusion method (17 4 , 8% (wt/vol) NaCl, 0.049% (wt/vol) Na 2 HPO 4 , 4.8% (wt/vol) HEPES (pH 7.4)], Invitrogen, Carsbad, CA. Livers were then perfused with 0.05% (vol/vol) collagenase (Roche, Rockford, IL) in Hanks' balanced salt solution for 10 min, removed, dissected, and passed through a 12-gauge needle. Washed cell pellets were then seeded at a density of 1 ϫ 10 6 cells per well in M199 medium with Earle salts (Invitrogen), 10% (vol/vol) heat-inactivated fetal bovine serum, 50 g/ml streptomycin, 50 U/ml penicillin, 2.0 mM L-glutamine, 20 ng/ml human epidermal growth factor (BD Biosciences, San Jose, CA), and 50 nM bovine insulin (Sigma, St. Louis, MO). Cells were cultured at 37 C, 5% CO 2 , for 3-4 d, then switched to serum-free media and treated with dexamethasone for various times.
In vitro culture of kidney IMCD3 cells
Mouse IMCD3 cells were grown to confluence in DMEMHam 12 (Sigma) containing 10% fetal calf serum and switched to serum-free medium 24 h before the addition of dexamethasone. Time course experiments were performed with a 10 Ϫ6 M dose of dexamethasone over a 0-, 0.5-, 1-, 2-, and 4-h time period. Dose-dependent experiments were performed for 3 h with doses of 0, 1, 10, 100, and 1000 nM of dexamethasone and for 3 h with a 10 Ϫ6 M dose of dexamethasone containing a 1-M dose of RU-486 (Misopristone, Sigma).
Isolation of total RNA
Total RNA was prepared from mouse liver and kidney by homogenization in TRIzol reagent (Life Technologies, Inc./BRL, Rockville, MD), as previously described (16) . For microarray analysis, RNA was further purified using an RNeasy cleanup kit (Qiagen, Valencia, CA).
Whole mouse genome gene expression microarray analysis
Liver samples were isolated from GR-null and wild-type adult mice (n ϭ 3) 3 h after treatment with dexamethasone (200 g/ 100 g body weight) and total RNA purified. RNA quality was determined using the Agilent Bioanalyser 2100 (Agilent, Santa Clara, CA) and the NanoChip protocol before microarray experiments. Three micrograms of RNA were subjected to rRNA removal procedure using RiboMinus Human/Mouse Transcriptome Isolation Kit (Invitrogen) and labeled using the Affymetrix WT cDNA Amplification kit (Affymetrix, Santa Clara, CA). The cDNA was fragmented using the apurinic-apyrimidic endonuclease 1 and uracil DNA glycosylase and quality checked using the Agilent Bioanalyser 2100 using the NanoChip protocol. The fragmented single-stranded cDNA was end labeled using terminal deoxynucleotidyl transferase enzyme from the WT Terminal Labeling kit (Affymetrix). Five micrograms of labeled cDNA was hybridized to the Affymetrix MouseExon 1.0 ST Array GeneChip (Affymetrix; catalog no. 900817) at 45 C for 16 h on a rotating wheel at 60 rpm. Chips were washed using the Fluidics Station 450 (Affymetrix) and scanned using the GeneChip Scanner 3000450 (Affymetrix). The scanner operating software, GCOS, converted the signal on the gene chip into a DAT file, which was used for generating a CEL file for analysis. The Affymetrix CEL files were imported into Partek Genomics Suite software package, version 6.2, build 6.06.0517 (Partek Inc., St. Louis, MO). Differentially regulated gene expression was identified using the predefined workflow for exon array. Expression values were background corrected using the GCRMA algorithm (Robust multiarray analysis with correction for GC content; 18). The data were normalized using quantile normalization (19) and summarized using Median Polish algorithm. Principal components analysis was used to transform gene expression information into variance-based information.
Synthesis of cDNA and real-time PCR
Total RNA from wild-type and GR-null mouse liver, kidney, and colon was transcribed into cDNA using random hexamers and M-MLV reverse transcriptase, RNase H Minus, Point Mutant (Promega, Madison, WI). Primer pairs were designed using Primer3 software (20) . Primers for quantitative real-time PCR (qRT-PCR) were Ddit4, forward-ACCTGTTCGAGGCAGCTATC, reverse-TCCCGAATGATCCTAACACC; Megf9, forward-GGGAA-CACTGTGAAGAATGC, reverse-CTCCAGATTCAATGGT-GCAA; Fkbp5, forward-CCAAGGCCAGGTTATCAAAG, reverse-CAGCCGAGCCATAAGCAT; melanocortin 2 receptor accessory protein (Mrap), forward-CAAGCATTCCATTGT-CATCG, reverse-AGAAAGAGGAGCACCACGAA; Sult1d1, forward-TGGAACAACTTGGGTCAGTG, reverse-AAGCTC-CATGAATGGTACTCG; Sult1e1, forward-GATGATCTA-TCTTTGCCGGAAC, reverse-AGGAACCATACGGAACT-TGC; and TAT, Forward-GTGGAATTCACAGAGCGG, reverse-GCCTATTTGTCACACTCC. Assays (in triplicate) were repeated at least twice with the 18S ribosomal RNA as a normalizing control. Cycling was performed using Platinum SYBR Greener qPCR SuperMix (Invitrogen, Carlsbad, CA) on a RotorGene 3000 (Corbett Research, Sydney, New South Wales, Australia). qRT-PCR data were analyzed using RotorGene 6.0 software (Corbett Research), and differential expression was determined using the comparative ⌬-⌬ CT method (21) .
Northern blot analysis
Total RNA (15 g) was separated in 1.2% agarose/2.2 M formaldehyde gels and blotted onto Genescreen Plus nylon membranes for Northern blot analysis by hybridization with 32 Plabeled DNA probes. A radioactive DNA probe for TAT, SDH, PEPCK, and TO was generated using the Prime-a Gene Labeling system (Promega) using isolated insert DNA. All filters were hybridized at 42 C in Ultrahyb buffer (Ambion, Austin, TX) and washed at 45 C in 0.1ϫ saline sodium citrate (SSC), 0.1% sodium dodecyl sulfate (SDS), two times for 15 min each. Filters were rehybridized with a 32 P-labeled 323-bp cDNA fragment of mouse cytochrome oxidase to control for RNA loading.
In situ hybridization
Frozen tissue sections (10 m) were fixed in 4% paraformaldehyde, treated with 0.1% diethylpyrocarbonate (Sigma), and 20 g/ml Ϫ1 proteinase K, and then fixed in 4% paraformaldehyde. Slides were prehybridized 50% formamide, 5ϫ SSC, 1% SDS, 100 g/ml Ϫ1 yeast tRNA, 500 g/ml Ϫ1 Heparin in a humidified chamber for 2 h at 60 C. A 987-bp fragment of the mouse Sult1d1 gene (complementary to nucleotides 254-1065 spanning exons 2-8 of the sult1d1 mRNA) was subcloned into pBluescript II SK (ϩ) to synthesize digoxigenin-labeled riboprobes, using the digoxigenin RNA labeling kit (Roche). An 11␤-HSDII antisense probe complementary to a 530-bp fragment of exon 5 of the 11␤-HSDII mouse gene was used as a positive control for staining the collecting duct as reported previously (22) . Hybridizations with probes were performed at 60 C for 18 -20 h. Coverslips were removed in 50% Formamide, 5ϫ SSC, and 1% SDS; sections were treated with 20 g/ml Ϫ1 ribonuclease A for 30 min in 0.5 M NaCl, 10 mM Tris HCl, and 0.1% Tween 20, and washed in the same solution. Slides were finally washed in 50% Formamide, 2ϫ SSC, and 0.1% SDS at 60 C. Slides were preblocked for 2 h at room temp [10% fetal sheep serum, 1ϫ Levamisole, and 1% Blocking Reagent (Roche) in 0.1 M maleicacid, 0.15 M NaCl(pH 7.5), 0.1% tween] before overnight incubation with block solution containing the antidigoxigenin antibody (1:1000 antidigoxigenin; Roche). Omission of the antidigoxigenin antibody to one section served as a negative control. Slides were washed in 0.1 M maleicacid, 0.15 M NaCl(pH 7.5), 0.1% tween and developed in BM purple substrate (Roche; category no. 11442074001).
Sulfotransferase assay
Tissue cytosol extracts were prepared by homogenizing tissue in 5 mM KPO 4 buffer (pH 6.5) containing 0.25 M sucrose and used for the SULT sulfotransferase assay. The assay was carried out using [ 35 S]-PAPS (PerkinElmer, Waltham, MA) as sulfate donor as previously described. In brief, 50 g/ml of total liver and kidney cytosolic extract was used with 1 M of dopamine substrate. Colon cytosolic extract was used as a negative control. After the reactions, free [
35 S] was removed by extracting with barium hydroxide and zinc sulfate. A 500-l aliquot of the aqueous phase was then counted in a scintillation counter.
Chromatin immunoprecipitation (ChIP) assay
Dimethylsulfoxide-or dexamethasone-treated IMCD3 cells were used for ChIP assays using a GR antibody M-20 (Santa Cruz Biotechnology, Santa Cruz, CA) and the chromatin immunoprecipitation kit (Millipore Billerica, MA). The primers for the described SGK-1 (serum and glucocorticoid-regulated kinase-1; a control glucocorticoid-responsive renal gene) and GRE were 5Ј-ctaactcgccacctcctcac-3Ј and 5Ј-tcccagaacttggaagagga-3Ј; for Sult1d1, Sult1e1, and GRE, 5Ј-ggggaattgagaccattgat-3Ј and 5Ј-tccagcccttcaaaggataa-3Ј; for TAT and GRE, 5Ј-ttctctatcgcagggagagc-3Ј and 5Ј-tttcagggacataccatgacac-3Ј; and for control region and GRE, 5Ј-ctcgttttcttgtttctaccacag-3Ј and 5Ј-caaactcacgacaatcaacaca-3Ј.
Statistical analysis
For Northern blot analyses, RNA levels were quantified by densitometry on a Storm Phosphorimager (Molecular Dynamics, Sunnyvale, CA) using ImageQuant software and standardized to the expression of 18S rRNA with statistical significance set at P Ͻ 0.05. qRT-PCR and sulfotransferase assays were tested for significance via one-way ANOVA. All results are expressed as mean Ϯ SEM. Normalized microarray data were subjected to ANOVA model using the Bonferroni method (23) . An adjusted probability value was calculated on the basis of the false discovery rate (24, 25) and on the original probability value (Յ0.001) from ANOVA. Genes with a change of 1.5-fold or more in signal intensity and false discovery rate of less than 0.05 were considered differentially expressed.
Results
Whole genome hepatic gene expression microarray analysis of GR-null mice
Before gene microarray analysis, total RNA samples from dexamethasone-treated wild-type and GR-null mice were analyzed for glucocorticoid regulation of previously well-characterized gluconeogenic enzyme target genes. Specific mRNA levels were measured at 0 h, 3 h, 6 h, and 24 h after dexamethasone treatment by Northern blot analysis (Fig. 1) . Results showed that the mRNA levels of PEPCK, SDH, TAT, and TO were strongly induced by dexamethasone in wild-type mice but were ablated or severely blunted in hepatic RNA from dexamethasonetreated GR-null mice, consistent with the predicted lack of a normal GR-mediated response in these mice. These hepatic target genes showed an acute response after 3 h of dexamethasone treatment in wild-type mice, with the mRNA levels of some genes such as PEPCK and SDH returning to basal levels after 6 h. Therefore, RNA samples from GR-null and wild-type mice 3 h after dexamethasone treatment were chosen to screen for additional differentially expressed GR target genes using whole genome gene expression microarray analysis.
To identify novel GR-regulated genes, liver RNA from wild-type and GR-null mice (n ϭ 4) 3 h after dexamethasone treatment were analyzed using Affymetrix mouse whole-genome exon microarray slides that contained 36,000 separate gene sequence features representing nearly all genes expressed from the mouse genome. Final analysis identified a total of 120 genes that were significantly increased at least 2-fold in liver RNA of wild-type compared with GR-null mice (see supplemental data, published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). The number of genes suppressed by dexamethasone was smaller, with 33 genes significantly reduced in RNA levels by at least 2-fold in liver RNA of GR-null compared with wild-type control mice. A shortened list detailing positive GR-regulated genes is shown in Table 1 . Analysis of the 16 most positively regulated genes in wild-type compared with GR-null liver revealed a number of known GR target genes such as the metallothionine, PEPCK, SDH, TO, lipin 1, cdkn1A, and SDH genes. These microarray data identified a large number of genes associated with a variety of cellular processes, ranging from development to metabolism, immune response, and apoptosis.
To confirm the results of the microarray data, several of the most strongly differentially expressed target genes were analyzed using qRT-PCR with RNA from both GRnull and wild-type adult mice (Fig. 2) . These target genes were Ddit4, Fkbp5, Megf9, Sult1d1, and Sult1e1. Consistent with the microarray data, there was a dramatic induction of mRNAs, with most still having high levels after 6 h of dexamethasone treatment. Among these genes, Sult1d1 and Sult1e1 are known to be involved in the deactivation and metabolism of foreign substances (26, 27) . Sult1d1 is the only sulfotransferase in mice known to selectively inactivate catecholamines such as dopamine. We therefore further examined features of Sult1d1 as a glucocorticoid-responsive gene and assessed whether Sult1d1 was associated with attenuation of dopamine levels after glucocorticoid administration. 
Induction of the Sult1d1 gene by dexamethasone in primary mouse hepatocytes and the kidney in vivo
The effect of dexamethasone on mouse Sult1d1 expression was examined further with primary mouse hepatocytes (Fig. 3A) . Six hours after incubation of hepatocytes with dexamethasone, Sult1d1 mRNA levels increased significantly 8-fold compared with control-treated primary hepatocytes. These changes were consistent with those measured in mouse liver in vivo using qRT-PCR (Fig. 2) .
TAT and Sult1e1 were used as positive markers of glucocorticoid induction in these cultured cells and responded in a similar way to Sult1d1 with a significant 11-fold and 2-fold induction, respectively, after dexamethasone treatment. The observed dexamethasone-induced increase in Sult1d1 mRNA levels was blocked by coadministration of the GR antagonist RU-486. RU-486 also blocked induction of TAT and Sult1e1 mRNA and further demonstrated that GR is responsible for mediating the induction of Sult1d1 mRNA by glucocorticoids in the liver.
Two other tissues with high activities in Sult1d1 are kidney and colon (28) . To investigate induction of Sult1d1 mRNA levels by glucocorticoids in these tissues, real-time PCR was used to measure Sult1d1 mRNA levels in total RNA from wild-type and GR-null mice (Fig. 3B) . Six hours after dexamethasone treatment, there was no significant change in Sult1d1 mRNA levels in colon total RNA between wild-type and GRnull mice. In kidney total RNA, however, there was a significant 2-fold increase in Sult1d1 mRNA levels after dexamethasone treatment in wild-type compared with GR-null mice (Fig. 3C) . In contrast, the levels of Sult1e1 mRNA in kidney were virtually absent compared with Sul1d1 mRNA levels and in contrast to the liver, where Sult1e1 mRNA was induced approximately 250-fold by dexamethasone. No induction Sult1e1 mRNA was detected in total RNA from the kidney (Fig. 3D) . This suggests that induction of Sult1e1 is restricted to the liver, whereas induction of Sult1d1 by glucocorticoids can be detected in both the liver and the kidney. Sult1d1 mRNA levels and enzymatic activity are induced by glucocorticoids in kidney collecting duct cells Localization of Sult1d1 expression in the kidney has so far not been well described, so this was examined by in situ hybridization of frozen sections of mouse adult kidney (Fig. 3, E-G ). An antisense Sult1d1 cDNA probe derived from exons 2-9 of the mouse Sult1d1 gene hybridized to the collecting duct cells of the kidney (Fig. 3F) , which was similar to specific labeling for the enzyme 11␤-HSDII (Fig.   3E ), a previously reported marker of renal collecting duct cells (25) . These cells have previously been shown to have high levels of GRs (29) . To examine specific regulation of the Sult1d1 gene by glucocorticoids in these cells, the mouse IMCD3 cell line was treated with dexamethasone and found to rapidly increase Sult1d1 mRNA levels in a dose-and time-dependent manner (Fig. 4) . As shown in Fig. 4A , a low dose of 10 nM dexamethasone for 3 h induced Sult1d1 mRNA levels 3-fold compared with vehicle control-treated cells, whereas a dose of 1 M dexamethasone increased Sult1d1 mRNA levels approximately 4.5-fold compared with controltreated cells. In a time-course study, Sult1d1 mRNA expression was already significantly elevated 1 h after dexamethasone treatment, with a maximal 5-fold increase after 4 h (Fig. 4B) . Coadministration of RU-486, a GR antagonist, blocked the dexamethasone-induced expression of Sult1d1 mRNA (Fig. 4C) .
Functional Sult1d1 enzymatic activity was measured via a sulfotransferase assay with dopamine as a sulfate donor as shown in Fig. 4D . Consistent with previous findings, dexamethasone increased the level of dopamine sulfation by 3.6-and 12.5-fold, respectively, in liver and kidney cytosolic extracts prepared 6 h after dexamethasone-treated wild-type mice. Not unexpectedly, levels of dopamine sulfation in colon tissue extracts were not altered 6 h after dexamethasone treatment. These results suggest that Sult1d1 is the primary functional sulfotransferase that inactivates dopamine in both the liver and the kidney of the mouse.
Sult1d1 gene expression is induced by glucocorticoids via an active GRE upstream of the adjacent Sult1e1 gene
To understand the molecular transcriptional mechanism by which GR regulates Sult1d1 gene expression, we analyzed the promoter and 5Ј upstream region of mouse Sult1d1 gene to look for putative GREs. Analysis of 50 kb upstream of the Sult1d1 gene transcription start site included the neighboring Sult1e1 gene that is situated only 2-3 kb upstream of the Sult1d1 gene. The only potential GRE identified in this entire region was found approximately 17 kb upstream of the Sult1e1 gene and approximately 39 kb upstream of the Sult1d1 transcription start site (Fig. 5, A and B) . This potential GRE corresponded to a GRE (12) 3 . A, The effect of dexamethasone on Sult1d1 mRNA levels in primary mouse hepatocytes. Primary hepatocytes were incubated with vehicle control and dexamethasone (10 Ϫ6 M) with or without the GR antagonist RU-486. After 3 h of incubation, mRNA levels for TAT, Sult1d1, and Sult1e1 were measured by qRT-PCR analysis. B, Time-course response to dexamethasone of Sult1d1 mRNA levels in mouse kidney. The effect of 6 h dexamethasone treatment on Sult1d1 mRNA expression in the colon is also shown. Sult1d1 mRNA levels in both WT and GR-null mice were analyzed by qRT-PCR at 0 h, 3 and 6 h after mice had been treated with a single dose of dexamethasone. Black bars represent wild-type mice. White bars represent GR-null mice. qRT-PCR analysis of Sult1d1 (C) and Sult1e1 (D) gene expression in whole liver and kidney after 6 h of dexamethasone treatment. Black bars represent vehicle-treated mice. White bars represent dexamethasone-treated mice. Col, Colon; Dex, dexamethasone; Kid, kidney. Analysis of mRNA levels for genes of interest was standardized to levels of 18S rRNA. All values are the mean Ϯ SEM (n ϭ 4). *, P Ͻ 0.05; **, P Ͻ 0.005; #, P Ͻ 0.001. E-G, Localization of Sult1d1 mRNA in the collecting duct of mouse kidney by in situ hybridization. A digoxigeninlabeled mouse Sult1d1 antisense cDNA probe was hybridized to tissue sections of whole kidney from wild-type mice. Four sections per animal (and four animals per group) were analyzed. One representative section from each group is shown. Shown in lightfield at 20ϫ magnification are the collecting ducts of the kidney: E, 11␤-HSDII antisense probe; F, Sult1d1 antisense (AS) probe; G, Sult1d1 sense (S) probe.
Sult1e1 gene in the liver and lies 17 kb upstream of the transcription start site for Sult1e1 (12) . We confirmed binding of GR to this GRE in primary hepatocytes 6 h after treatment with dexamethasone by using ChIP analysis and detected identical binding of GR to this region of DNA (Fig. 5C ). The mouse TAT gene GRE was used as a positive control for GR binding in these cells. Kidney IMCD3 cells were then used to investigate binding of GR to this GRE because Sult1e1 gene expression is not induced in these cells after dexamethasone treatment (data not shown). ChIP analysis (Fig. 5D) showed positive binding of GR to both the SGK-1 and Sult1e1-Sult1d1 GREs after 1.5 h and 3 h of dexamethasone treatment compared with a proximal control region of the Sult1d1 promoter containing no GRE. This binding of GR to these GREs was attenuated by prior administration of RU-486, a GR antagonist (Fig. 5D ). This suggests that this GRE mediates only induction of the Sult1d1 gene in the kidney and therefore that both the Sult1d1 and the Sult1e1 genes potentially share a common GRE distal and 5Ј to the Sult1e1 gene that is likely responsible for differential glucocorticoid induction of these genes in liver vs. kidney cells.
Discussion
Elevated glucocorticoid levels during fasting have a major effect on metabolism, where they are responsible for regulating key enzymes in a number of metabolic pathways such as gluconeogenesis in the liver. This study with GRnull mice using whole genome microarray analysis has identified both known and a set of a novel GR-regulated gene targets in the liver and provides a unique insight into the molecular basis for the hepatic regulation of metabolic and detoxification pathways by glucocorticoids. Expression analysis of liver RNA by microarrays and qRT-PCR 3 h and 6 h after dexamethasone stimulation detected induction of previously well-characterized glucocorticoidregulated target genes such as the gluconeogenic enzymes genes TAT and PEPCK, metallothionein 1 and 2 (11), Lipocalin 2, Lipin 1, and Cdkn1a or P21 (30) .
To confirm the validity of the microarray data, several of the most strongly differentially expressed genes were analyzed using real-time PCR in RNA from both GR-null and wild-type adult mice at various times after dexamethasone treatment. Consistent with the microarray data, this temporal analysis showed dramatic induction of specific target genes after 3 h, with most still at high levels 6 h after dexamethasone treatment. Genes such as Ddit4 and Lipin 1 have been identified in the present study as genes that potentially underlie the mechanisms of known physiological actions of glucocorticoids, such as the regulation of apoptosis and lipid metabolism, respectively (31, 32) . The Mrap was also significantly induced by dexamethasone. This protein has a major role in the trafficking and cell-surface expression of the ACTH receptor, a G protein-coupled receptor. Previous reports have shown that mutations in Mrap cause 25% of cases of familial glucocorticoid deficiency syndrome that have abnormally low levels of cortisol due to disruptions in ACTH signaling (33) . This finding that Mrap is induced by dexamethasone in the liver suggests a potential autoregulatory role for glucocorticoids in the maintenance of glucocorticoid synthesis, most likely in the adrenal gland; however, this awaits formal demonstration with additional studies.
Two members of the sulfotransferase gene family, Sult1e1 and Sult1d1, were also steroid-induced in the liver after dexamethasone treatment. Sulfotransferases belong to the phase 2 class of cytosolic detoxification enzymes that transfer sulfate groups to specific substrates such as hormones, neurotransmitters, or exogenous drugs (28) . This modification normally inactivates the substrate and converts them into more water-soluble excretable forms. The sulfotransferase superfamily has been divided on amino acid homology into five subfamilies: Sult1 (phenol sulfotransferases), Sult2 (hydroxysteroid endo.endojournals.orgsulfotransferases), Sult3, Sult4, and Sult5 (28) . Humans have at least 11 functional SULT genes and rodents a similar number, but there are species-specific differences in expression (34) . Recently, a link between Sult1e1 and glucocorticoids has been reported, and Sult1e1 is now believed to be the major sulfotransferase responsible for estrogen sulfation in the liver (12, 26, 35) . This recent study confirmed previous reports that glucocorticoids were able to inhibit uterine responses stimulated by estrogens (36, 37) . In addition, Sult1e1 has been implicated in the therapeutic development of human breast cancer as dexamethasone-induced Sult1e1 expression inhibited estrogenstimulated MCF-7 cell proliferation. In humans, the Sult1d1 gene is a pseudogene due to the presence of an in-frame stop codon (38) . In spite of this, another sulfotransferase called Sult1a3 has been found to selectively catalyze "parent" amine sulfation in the human kidney (39) . This illustrates an interesting species difference in which different sulfotransferases in rodents and humans are responsible for the deactivation of catecholamines. Most interestingly, a recent study has shown increased Sult1a3 mRNA levels after dexamethasone treatment in the human HepG2 cell line (40) , suggesting this sulfotransferase in humans is potentially responsible for reducing catecholamine levels after the stress response. However, Sult1d1 has been less well studied despite a recent report showing it has the highest substrate affinity toward catecholamines such as dopamine and its derivatives, including 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxymandelic acid, and 3,4-dihydroxyphenylene glycol (41, 42) . From kinetic data, the value of maximum velocity per kilometer for DOPAC is 20-fold higher than that for dopamine, suggesting that DOPAC is a selective substrate for Sult1d1. The importance of Sult1d1in detoxification has been described in the canine colon (43) , where its proposed role in basal metabolism is to deaminate dietary dopamine substances from exogenous sources (44) . Because Sult1d1 mRNA levels did not change after dexamethasone treatment in colon, we do not feel that in vivo dexamethasone treatment would stimulate this activity in the colon.
The tissue distribution of these sulfotransferase enzymes varies considerably. Sult1e1 is mainly distributed in the gonads of male mice and placenta of female mice, whereas Sult1d1 is more broadly expressed, with levels highest in the kidney, followed by the colon and then the liver (28, 45) . This was consistent with our observation with levels for sult1e1 in the kidney being virtually absent both before and after treatment. In contrast, detailed measurement with real-time PCR and sulfotransferase assays in both kidney and liver tissue after dexamethasone treatment showed pronounced induction of Sult1d1 expression in the kidney and liver. This induction by dexamethasone in the liver was confirmed at a cellular level using primary mouse hepatocytes, and cotreatment with RU-486 confirmed that induction is via a GR-mediated signaling pathway.
Catecholamines such as dopamine are biotransformed and deactivated via a number of enzymatic pathways. In the central nervous system, catecholamines are mainly deactivated by the reuptake via the dopamine transporter, then enzymatically broken down by catechol-O-methyl transferase and monoamine oxidase. In contrast, dopamine secreted into the bloodstream only has a 10 min half-life in blood, with the free form constituting less than 2% of total plasma dopamine (46) . The remaining dopamine in blood exists predominantly as sulfate or glucuronide conjugate forms (47) . As such, the inactivation of dopamine in blood is critical in maintaining metabolic homeostasis. This is highlighted in dopamine derivatives such as DOPAC, which modulates the toxicity induced by nitric oxide in PC-12 cells via mitochondrial dysfunction (48) . Studies using in situ hybridization and in vitro experiments with IMCD3 cells clearly localized Sult1d1 activity to renal collecting duct cells. Because the collecting ducts are the site of renal clearance, these results suggest that renal Sultd1is partly responsible for the excretion of catecholamines to reduce levels of dopamine derivatives in the bloodstream. Furthermore, studies have shown that the organic cation transporter (Oct2) has the same localization as Sult1d1 in the collecting duct, and it is possible that dopamine and DOPAC may be transported into the renal tubule by Oct1/2 and then sulfated with Sult1d1 in mice (42) .
Analysis of the mouse Sult1d1 gene promoter and upstream region via ChIP analysis suggests that the Sult1d1 and Sult1e1 genes may share a common GRE. This has also been observed in the mouse metallothionein genes 1 and 2, which share a pair of GREs approximately 7 kb upstream of the metallothionein 1 gene promoter (49) . Gong et al. (2008) detected a functional GRE approximately 17 kb upstream of the start site of transcription of the Sult1e1 gene (12) . We confirmed the binding of GR in primary hepatocytes and detected identical binding to this region of DNA. In renal collecting duct cells, binding of GR to this GRE induced Sult1d1 but not Sult1e1 mRNA levels after dexamethasone treatment. In summary, we have demonstrated that in mice during the stress response, glucocorticoids act to stimulate levels of Sult1d1 in the liver and kidney. This strongly suggests a pathway whereby glucocorticoids attenuate the cellular actions of elevated catecholamine levels circulating in the blood. In the kidney, renal Sult1d1 may act to facilitate sulfated dopamine excretion in the urine. Further studies will need to investigate the long-term effects of glucocorticoids on Sult1d1 induction and activity and the impact of this regulation on catecholamine and other dopamine-regulated actions in the brain and cardiovascular system.
